<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Digoxin immune Fab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Digoxin immune Fab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Digoxin immune Fab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="13231" href="/d/html/13231.html" rel="external">see "Digoxin immune Fab: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="15551" href="/d/html/15551.html" rel="external">see "Digoxin immune Fab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160237"><span class="drugH1">Brand Names: US</span>
<ul>
<li>DigiFab</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866597"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>DigiFab</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F160256"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F160240"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each vial of digoxin immune Fab 40 mg will bind ~0.5 mg of digoxin.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a75959b-3dbf-4d81-beae-9f48db6b9b2a">Digoxin toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Digoxin toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For the most contemporary approach to patient selection and dosing recommendations, consultation with a poison control center or a clinical toxicologist is highly recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Estimation of a full neutralizing dose is based on the body burden of digoxin. This may be calculated if the amount ingested is known or the postdistribution serum drug level is known. Round the dose up to the nearest whole vial. If the amount ingested is unknown, general dosing guidelines should be used. Empirical dosing of digoxin immune fab prior to steady-state digoxin serum concentrations may result in an overestimation of the required dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26057142','lexi-content-ref-25379735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26057142','lexi-content-ref-25379735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute toxicity, full neutralizing dose:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acute ingestion of unknown amount:</b>
<b>IV:</b> Initial: 10 vials; if needed, administer a second dose of 10 vials (20 vials total is adequate to treat most life-threatening ingestions).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acute ingestion of known amount:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Based on number of tablets or capsules ingested:</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Step 1: Calculate total body load (mg)</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Digoxin capsules: </i>
<b>Note: </b>This assumes 100% bioavailability of digoxin.</p>
<p style="text-indent:-2em;margin-left:14em;">Total body load (mg) = Amount (mg) digoxin capsules ingested</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Digoxin tablets: </i>
<b>Note: </b>This assumes 80% bioavailability of digoxin.</p>
<p style="text-indent:-2em;margin-left:14em;">Total body load (mg) = 0.8 x (amount [mg] digoxin tablets ingested)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>
<i>Step 2: Calculate number of vials needed</i></b></p>
<p style="text-indent:-2em;margin-left:12em;">Digoxin Immune Fab Dose (vials) = Total body load (mg) x 2</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Alternatively,</b> the following table gives an estimation of the number of vials needed based on the number of <b>digoxin </b>tablets or capsules ingested.</p>
<table border="1" data-table-id="digoxfab" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Approximate Dose of Digoxin Immune Fab (in vials) for Reversal of a Single Large Digoxin Overdose</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="top">
<tr>
<th align="center">
<p style="text-indent:0em;">Number of Digoxin Tablets or Capsules Ingested<sup>1</sup></p></th>
<th align="center">
<p style="text-indent:0em;">Dose of Digoxin Immune Fab</p>
<p style="text-indent:0em;">(# of Vials)</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>1</sup>250 mcg tablets with 80% bioavailability or 200 mcg capsules with 100% bioavailability.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">25</p></td>
<td align="center">
<p style="text-indent:0em;">10</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">75</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">100</p></td>
<td align="center">
<p style="text-indent:0em;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">150</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">200</p></td>
<td align="center">
<p style="text-indent:0em;">80</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic toxicity, full neutralizing dose:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients who receive digoxin therapeutically often require lower doses than those with acute overdosage because their total body burden of digoxin is generally low comparatively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Serum digoxin concentration unknown:</b>
<b>IV:</b> 6 vials is adequate to reverse most cases of toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Steady-state serum <span style="text-decoration: underline">digoxin</span> concentration known:</b>
<b>Note:</b> If the calculated dose based on the digoxin concentration is different from the estimated dose based on the known ingested amount (if available), use the higher dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Digoxin Immune Fab Dose (vials) = (serum digoxin concentration [ng/mL] x weight [kg]) / <b>100</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Alternatively,</b> the following table gives an estimation of the number of vials needed based on the steady-state serum digoxin concentration.</p>
<table border="1" data-table-id="digoxadu" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Adult Dose Estimates of Digoxin Immune Fab (in # of Vials) From Steady-State Serum Digoxin Concentration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2" valign="middle">
<p style="text-indent:0em;">Patient Weight (kg)</p></th>
<th align="center" colspan="7" valign="middle">
<p style="text-indent:0em;">Serum Digoxin Concentration (ng/mL)</p></th></tr>
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">1</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">2</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">4</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">8</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">12</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">16</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">20</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">40</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">60</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">12 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">70</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">6 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">9 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">11 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">14 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">80</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">13 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">16 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">100</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">4 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">12 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">16 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">20 vials</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute or chronic toxicity, low dose (off-label dose): Note: </b>A "low dose" may be sufficient for some patients with acute or chronic digoxin toxicity where neither amount ingested or steady-state level is known, so long as life-threatening toxicity is not present; consultation with a poison control center or a clinical toxicologist is highly recommended for appropriate patient selection and dosing. The "low dose" approach is based on the pharmacokinetic assumption that 1 to 4 vials of digoxin immune Fab is sufficient to bind the free central compartment digoxin in most patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25089630','lexi-content-ref-27118413','lexi-content-ref-34424803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25089630','lexi-content-ref-27118413','lexi-content-ref-34424803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acute digoxin toxicity: </i>
<b>IV:</b> 2 vials; may repeat every ~1 hour if there is no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25089630','lexi-content-ref-34424803']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25089630','lexi-content-ref-34424803'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chronic digoxin toxicity: </i>
<b>IV:</b> 1 to 2 vials; may repeat every ~1 hour if there is no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25089630','lexi-content-ref-27118413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25089630','lexi-content-ref-27118413'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991693"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution since digoxin-digoxin immune Fab complex is renally eliminated. Patients should undergo prolonged monitoring for recurrence of toxicity.</p></div>
<div class="block doha drugH1Div" id="F50989010"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F160241"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F160250"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13231" href="/d/html/13231.html" rel="external">see "Digoxin immune Fab: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a75959b-3dbf-4d81-beae-9f48db6b9b2a">Digoxin toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<span style="text-decoration: underline">
<b>Digoxin toxicity</b></span>: Infants, Children, and Adolescents: <b>Note:</b> Estimation of the dose is based on the body burden of digitalis. This may be calculated if the amount ingested is known or the post-distribution serum drug concentration is known (round the dose up to the nearest whole vial). If the amount ingested is unknown, general dosing guidelines should be used.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ingestion of <span style="text-decoration: underline">unknown</span> amount:</b> IV: Initial: 10 vials; if needed, may administer a second dose of 10 vials (to avoid a febrile reaction); a total dose of 20 vials is adequate to treat most life-threatening ingestions. In small children (&lt;20 kg), it is important to monitor for fluid overload.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ingestion of <span style="text-decoration: underline">known</span> amount:</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Step 1: <i>Calculate total body load (mg): </i>If parenteral overdose of digoxin or from ingestion or oral capsules, total body load of digoxin is equal to the dose administered. If oral digoxin ingestion/overdose from elixir or tablets, the total body load should be calculated based on the following equation:</p>
<p style="text-indent:-2em;margin-left:6em;">Total body load (mg) = 0.8 x [amount (mg) digoxin tablets or elixir ingested]</p>
<p style="text-indent:-2em;margin-left:4em;">Step 2: <i>Calculate number of vials needed: </i>Each vial of digoxin immune Fab 40 mg will bind ~0.5 mg of digoxin.</p>
<p style="text-indent:-2em;margin-left:6em;">Digoxin Immune Fab Dose (vials) = Total digoxin body load (mg) / 0.5 mg/vial</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Based on steady-state serum digoxin concentration: IV: </b>
<i>Dose may be determined by estimation with the following tables or calculated based on the following equations for either mg dose or number of vials needed (use precaution to ensure appropriate equation):</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Infants and Children ≤20 kg may require smaller doses; calculate the dose in milligrams (mg)</p>
<p style="text-indent:-2em;margin-left:6em;">Digoxin Immune Fab Dose (<b>mg</b>) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 100] x 40 mg/vial</p>
<p style="text-indent:-2em;margin-left:6em;">Digoxin Immune Fab Dose (<b>vials</b>) = (serum digoxin concentration [ng/mL] x weight [kg]) / 100</p>
<p style="text-indent:-2em;margin-left:4em;">The following tables give an estimation of the amount of Digoxin Immune Fab needed based on the steady-state serum digoxin concentration.</p>
<table border="1" data-table-id="inffab" frame="border" rules="all">
<caption style="text-align:center;">
<b>Infants and Children &lt;20 kg: Dose Estimates of Digoxin Immune Fab (in mg) From Serum Digoxin Concentration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2" valign="middle">
<p style="text-indent:0em;">Patient Weight</p>
<p style="text-indent:0em;">(kg)</p></th>
<th align="center" colspan="7">
<p style="text-indent:0em;">Serum Digoxin Concentration (ng/mL)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">1 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">2 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">4 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">8 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">12 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">16 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">20 ng/mL</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="8">
<p style="text-indent:0em;">
<sup>A</sup>Dilution of reconstituted vial to 1 mg/mL may be desirable.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">3</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg<sup>A</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2.5 mg<sup>A</sup></p></td>
<td align="center">
<p style="text-indent:0em;">5 mg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg</p></td>
<td align="center">
<p style="text-indent:0em;">14 mg</p></td>
<td align="center">
<p style="text-indent:0em;">19 mg</p></td>
<td align="center">
<p style="text-indent:0em;">24 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg<sup>A</sup></p></td>
<td align="center">
<p style="text-indent:0em;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg</p></td>
<td align="center">
<p style="text-indent:0em;">16 mg</p></td>
<td align="center">
<p style="text-indent:0em;">24 mg</p></td>
<td align="center">
<p style="text-indent:0em;">32 mg</p></td>
<td align="center">
<p style="text-indent:0em;">40 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10</p></td>
<td align="center">
<p style="text-indent:0em;">4 mg</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg</p></td>
<td align="center">
<p style="text-indent:0em;">16 mg</p></td>
<td align="center">
<p style="text-indent:0em;">32 mg</p></td>
<td align="center">
<p style="text-indent:0em;">48 mg</p></td>
<td align="center">
<p style="text-indent:0em;">64 mg</p></td>
<td align="center">
<p style="text-indent:0em;">80 mg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20</p></td>
<td align="center">
<p style="text-indent:0em;">8 mg</p></td>
<td align="center">
<p style="text-indent:0em;">16 mg</p></td>
<td align="center">
<p style="text-indent:0em;">32 mg</p></td>
<td align="center">
<p style="text-indent:0em;">64 mg</p></td>
<td align="center">
<p style="text-indent:0em;">96 mg</p></td>
<td align="center">
<p style="text-indent:0em;">128 mg</p></td>
<td align="center">
<p style="text-indent:0em;">160 mg</p></td></tr></tbody></table>
<table border="1" data-table-id="adultfab" frame="border" rules="all">
<caption style="text-align:center;">
<b>Children and Adolescents ≥40 kg: Dose Estimate of Digoxin Immune Fab (in # of Vials) From Serum Digoxin Concentration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Patient Weight (kg)</p></th>
<th align="center" colspan="7" valign="middle">
<p style="text-indent:0em;">Serum Digoxin Concentration (ng/mL)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">1 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">2 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">4 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">8 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">12 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">16 ng/mL</p></th>
<th align="center">
<p style="text-indent:0em;">20 ng/mL</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">40</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">60</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">12 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">70</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">6 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">9 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">11 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">14 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">80</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">10 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">13 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">16 vials</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">100</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1 vial</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">4 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">8 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">12 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">16 vials</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">20 vials</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic toxicity (serum digoxin concentration unavailable):</b> IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤20 kg: 1 vial is adequate to reverse most cases of toxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;20 kg and Adolescents: 6 vials is adequate to reverse most cases of toxicity</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109238"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no pediatric specific recommendations provided; use with caution; elimination of Fab-digoxin fragments may be prolonged with renal impairment; patients should have serum digoxin levels monitored closely (including unbound if possible) to identify/prevent recurrence of toxicity and to determine an appropriate time for re-digitalization (if applicable).</p></div>
<div class="block dohp drugH1Div" id="F51109239"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F160210"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Orthostatic hypotension, phlebitis, ventricular tachycardia (patients with atrial fibrillation; due to digoxin withdrawal), worsening of heart failure (due to digoxin withdrawal)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction, serum sickness</p></div>
<div class="block coi drugH1Div" id="F160225"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F160207"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypersensitivity reactions: Digoxin immune Fab is derived from ovine (sheep) Fab immunoglobulin fragments; hypersensitivity reactions (eg, anaphylactic or anaphylactoid reactions, delayed allergic reactions) are possible. Patients with allergies to sheep proteins and patients with prior exposure to ovine antibodies or ovine Fab may be at a higher risk for  anaphylactic reactions. In patients who develop an anaphylactic reaction, discontinue the infusion immediately and administer emergency care; balance the need for epinephrine against its potential risk in the setting of digitalis toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;">Processed with papain and may cause hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;">• Potassium imbalance: Patients experiencing acute digitalis toxicity may present with significant hyperkalemia due to shifting of potassium into the extracellular space. Upon treatment with digoxin immune Fab, potassium shifts back into the intracellular space and may result in hypokalemia.  Monitor potassium closely, especially during the first few hours after administration; treat hypokalemia cautiously when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Heart failure (HF): In patients chronically maintained on digoxin for HF, administration of digoxin immune Fab may result in exacerbation of HF symptoms due to a reduction in digoxin serum concentration. If reinitiation is required, consider postponing until Fab fragments have been eliminated completely; elimination may take several days or longer, especially in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal failure (experience limited); the Fab-digoxin complex will be eliminated more slowly. Toxicity may recur; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population.</p></div>
<div class="block foc drugH1Div" id="F160219"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DigiFab: 40 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F160203"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323111"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (DigiFab Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $5,518.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866598"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DigiFab: 40 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F160222"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by slow IV infusion over at least 30 minutes. May also be given by bolus injection if cardiac arrest is imminent (infusion-related reaction may occur). Stopping the infusion and restarting at a slower rate may help if an infusion-related reaction occurs.</p></div>
<div class="block admp drugH1Div" id="F52612559"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Administration by IV infusion over at least 30 minutes is preferable. May also be administered by bolus injection if cardiac arrest is imminent (infusion-related reaction may occur). If an infusion-related reaction occurs, discontinue the infusion and reinitiate at a slower rate.</p></div>
<div class="block use drugH1Div" id="F160220"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Digoxin toxicity:</b> Treatment of life-threatening or potentially life-threatening digoxin intoxication, including:</p>
<p style="text-indent:-2em;margin-left:4em;">- Acute digoxin ingestion (≥10 mg in adults; 4 mg [&gt;0.1 mg/kg] in children); resulting in serum concentration ≥10 ng/mL). <b>Note: </b>Serum digoxin concentrations do not reflect myocardial digoxin concentrations until distribution occurs (~4 to 6 hours). Therefore, an initially elevated concentration (in the absence of overt toxicity) may not indicate the use of digoxin immune fab. However, an initial serum concentration in excess of 10 ng/mL may be predictive of toxicity (Hack 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">- Chronic ingestion leading to steady state digoxin concentrations &gt;6 ng/mL in adults or &gt;4 ng/mL in children.</p>
<p style="text-indent:-2em;margin-left:4em;">- Manifestations of life-threatening digoxin toxicity due to overdose (severe ventricular arrhythmias, progressive bradycardia, second- or third-degree heart block not responsive to atropine, serum potassium concentration &gt;5.5 mEq/L in adults or &gt;6 mEq/L in children).</p></div>
<div class="block off-label drugH1Div" id="F53936965"><span class="drugH1">Use: Off-Label: Adult</span><p>Cardiac glycoside toxicity</p></div>
<div class="block cyt drugH1Div" id="F13299196"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6219862"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F160227"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>
<div class="block brc drugH1Div" id="F21121953"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if digoxin immune fab is excreted in breast milk. The manufacturer recommends caution be exercised when administering to  nursing women.</p></div>
<div class="block mop drugH1Div" id="F160217"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Prior to the first dose of digoxin immune Fab evaluate serum potassium, serum digoxin concentration, and serum creatinine; closely monitor serum potassium (eg, hourly for 4 to 6 hours; at least daily thereafter; elevated serum potassium is associated with increased morbidity and mortality (Hauptman 2016; Rezai 2018). Monitor temperature, blood pressure, and electrocardiogram after administration. <b>Total serum digoxin concentrations will rise precipitously following administration of digoxin immune Fab due to the presence of the Fab-digoxin complex; because digoxin bound to Fab fragments cannot result in toxicity, this rise has no clinical meaning. </b>Therefore, avoid monitoring total serum digoxin concentrations until the Fab fragments have been eliminated completely; this may be several days to weeks in patients with renal impairment (Ujhelyi 1995). Monitor for volume overload in children &lt;20 kg. Monitor for signs and symptoms of a hypersensitivity reaction.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with renal failure may experience a recurrence of toxicity; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population.</p></div>
<div class="block pha drugH1Div" id="F160206"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Digoxin immune antigen-binding fragments (Fab) are specific antibodies for the treatment of digitalis intoxication in carefully selected patients; binds with molecules of digoxin and is then excreted by the kidneys and removed from the body.</p></div>
<div class="block phk drugH1Div" id="F160224"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: IV: Digitalis toxicity: Improvement may be seen within 20 to 90 minutes (Betten, 2006)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.3 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 15 to 20 hours; may be increased up to 10-fold in patient with renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (concentrations declining within 5 to 7 days)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F160228"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Digitalis antidot</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Digibind | Digifab</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Digitalis antidot</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Digifab | Digitalis antidot</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Digitalis antidot</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Digibind | Digifab</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Digidot | Digifab</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Digibind | Digifab</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Digibind | Digifab</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Digibind | Digifab</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Digitalis antidot</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Digifab</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2188752">
<a name="2188752"></a>Antman EM, Wenger TL, Butler VP Jr, et al, “Treatment of 150 Cases of Life-Threatening Digitalis Intoxication With Digoxin-Specific Fab Antibody Fragments,” <i>Circulation</i>, 1990, 81(6):1744-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/2188752/pubmed" id="2188752" target="_blank">2188752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29316267">
<a name="29316267"></a>Arbabian H, Lee HM, Graudins A. Elderly patients with suspected chronic digoxin toxicity: a comparison of clinical characteristics of patients receiving and not receiving digoxin-Fab. <i>Emerg Med Australas.</i> 2018;30(2):242-248. doi: 10.1111/1742-6723.12873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/29316267/pubmed" id="29316267" target="_blank">29316267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aruna.1">
<a name="Aruna.1"></a>Aruna AS and Jue SG, “Digoxin Immune Fab Administration Following an Unexplained Increase in Serum Digoxin Concentration,” <i>J Pharm Sci Technol</i>, 1994, 10:246-9.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16946442">
<a name="16946442"></a>Betten DP, Vohra RB, Cook MD, et al. Antidote use in the critically ill poisoned patient. <i>J Intensive Care Med</i>. 2006;21(5):255-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/16946442/pubmed" id="16946442" target="_blank">16946442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B, "Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?" <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15862081">
<a name="15862081"></a>Bateman DN, "Digoxin-Specific Antibody Fragments: How Much and When?" <i>Toxicol Rev</i>, 2004, 23(3):135-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/15862081/pubmed" id="15862081" target="_blank">15862081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19262393">
<a name="19262393"></a>Bilbault P, Oubaassine R, Rahmani H, et al, “Emergency Step-by-Step Specific Immunotherapy in Severe Digoxin Poisoning: An Observational Cohort Study,” <i>Europ J Emerg Med</i>, 2009, 16(3):145-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/19262393/pubmed" id="19262393" target="_blank">19262393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25089630">
<a name="25089630"></a>Chan BS, Buckley NA. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. <i>Clin Toxicol (Phila).</i> 2014;52(8):824-836. doi:10.3109/15563650.2014.943907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/25089630/pubmed" id="25089630" target="_blank">25089630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34424803">
<a name="34424803"></a>Chan BS, Isbister GK, Chiew A, Isoardi K, Buckley NA. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). <i>Clin Toxicol (Phila)</i>. 2022;60(4):433-439. doi:10.1080/15563650.2021.1968422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/34424803/pubmed" id="34424803" target="_blank">34424803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27118413">
<a name="27118413"></a>Chan BS, Isbister GK, O'Leary M, Chiew A, Buckley NA. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). <i>Clin Toxicol (Phila).</i> 2016;54(6):488-494. doi: 10.1080/15563650.2016.1175620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/27118413/pubmed" id="27118413" target="_blank">27118413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26057142">
<a name="26057142"></a>Chhabra N, Valento M, Bryant SM, Aks SE. Digoxin-specific antibody fragment dosing: a case series. <i>Am J Ther.</i> 2016;23(6):e1597-e1601. doi:10.1097/MJT.0000000000000267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/26057142/pubmed" id="26057142" target="_blank">26057142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DigiFab.1">
<a name="DigiFab.1"></a>DigiFab (digoxin immune fab [ovine]) [prescribing information]. West Conshohocken, PA: June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19875723">
<a name="19875723"></a>Eyer F, Steimer W, Muller C, et al, “Free and Total Digoxin in Serum During Treatment of Acute Digoxin Poisoning With Fab Fragments: Case Study,” <i>Am J Crit Care</i>, 2010, 19(4):391-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/19875723/pubmed" id="19875723" target="_blank">19875723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28941873">
<a name="28941873"></a>Farag M, Badowski D, Koschny R, Skopp G, Brcic A, Szabo GB. Extracorporeal life support and digoxin-specific fab fragments for successful management of Taxus baccata intoxication with low output and ventricular arrhythmia. <i>Am J Emerg Med</i>. 2017;35(12):1987.e3-1987.e7. doi: 10.1016/j.ajem.2017.09.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/28941873/pubmed" id="28941873" target="_blank">28941873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15554746">
<a name="15554746"></a>Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. <i>Drug Saf.</i> 2004;27(14):1115-1133. doi: 10.2165/00002018-200427140-00004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/15554746/pubmed" id="15554746" target="_blank">15554746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hack.1">
<a name="Hack.1"></a>Hack JB. Cardioactive steroids. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. New York, NY: McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27039127">
<a name="27039127"></a>Hauptman PJ, Blume SW, Lewis EF, Ward S. Digoxin toxicity and use of digoxin immune Fab: insights from a national hospital database.<i> JACC Heart Fail.</i> 2016;4(5):357-364. doi: 10.1016/j.jchf.2016.01.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/27039127/pubmed" id="27039127" target="_blank">27039127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1993775">
<a name="1993775"></a>Hickey AR, Wenger TL, Carpenter VP, et al, “Digoxin Immune Fab Therapy in the Management of Digitalis Intoxication: Safety and Efficacy Results of an Observational Surveillance Study,” <i>J Am Coll Cardiol</i>, 1991, 17(3):590-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/1993775/pubmed" id="1993775" target="_blank">1993775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2371148">
<a name="2371148"></a>Kaufman J, Leikin J, Kendzierski D, et al, “Use of Digoxin Fab Immune Fragments in a Seven-Day-Old Infant,” <i>Pediatr Emerg Care</i>, 1990, 6(2):118-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/2371148/pubmed" id="2371148" target="_blank">2371148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21109316">
<a name="21109316"></a>Kockova R, Skvaril J, Cernohous M, et al, “Five Year Two Center Retrospective Analysis of Patients With Toxic Digoxin Serum Concentration,” <i>Internat J Cardiol</i>, 2011, 146(3):447-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/21109316/pubmed" id="21109316" target="_blank">21109316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29363354">
<a name="29363354"></a>Labossiere AW, Thompson DF. Clinical toxicology of yew poisoning. <i>Ann Pharmacother.</i> 2018;52(6):591-599. doi: 10.1177/1060028017754225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/29363354/pubmed" id="29363354" target="_blank">29363354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3970406">
<a name="3970406"></a>Leikin J, Vogel S, Graft J, et al, “Use of Fab Fragments of Digoxin-Specific Antibodies in the Therapy of Massive Digoxin Poisoning,” <i>Ann Emerg Med</i>, 1985, 14(2):175-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/3970406/pubmed" id="3970406" target="_blank">3970406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3286119">
<a name="3286119"></a>Martiny SS, Phelps SJ, and Massey KL, “Treatment of Severe Digitalis Intoxication With Digoxin-Specific Antibody Fragments, A Clinical Review,” <i>Crit Care Med</i>, 1988, 16(6):629-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/3286119/pubmed" id="3286119" target="_blank">3286119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Megarbane.1">
<a name="Megarbane.1"></a>Mégarbane B. Digitalis glycosides. In: Brent J, Burkhart KK, Dargan P, et al, eds. <i>Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient.</i> Cham, Switzerland: Springer International Publishing; 2017:807-819.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30083638">
<a name="30083638"></a>Misek R, Allen G, LeComte V, Mazur N. Fatality following intentional ingestion of<i> Cerbera odollam</i> seeds. <i>Clin Pract Cases Emerg Med.</i> 2018;2(3):223-226. doi:10.5811/cpcem.2018.5.38345<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/30083638/pubmed" id="30083638" target="_blank">30083638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25379735">
<a name="25379735"></a>Nordt SP, Clark RF, Machado C, Cantrell FL. Assessment of digoxin-specific fab fragment dosages in digoxin poisoning. <i>Am J Ther.</i> 2016;23(1):e63-e67. doi:10.1097/MJT.0000000000000127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/25379735/pubmed" id="25379735" target="_blank">25379735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rezai.1">
<a name="Rezai.1"></a>Rezai M, Delpasand F, Shirsavar K, et al. Investigation of factors affecting outcome of patients with acute digoxin intoxication in two academic emergency departments during 2004-2016. <i>J Surg Trauma</i>. 2018;6(3):108-113.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1763546">
<a name="1763546"></a>Schneider PJ, McCollam PL, and Osborn JJ, "Possible Dissociation of the Digibind-Digoxin Complex in Renal Failure," <i>DICP</i>, 1991, 25(11):1269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/1763546/pubmed" id="1763546" target="_blank">1763546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3382077">
<a name="3382077"></a>Shumaik GM, Wu AW, and Ping AC, “Oleander Poisoning: Treatment With Digoxin-Specific Fab Antibody Fragments,” <i>Ann Emerg Med</i>, 1988, 17(7):732-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/3382077/pubmed" id="3382077" target="_blank">3382077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith SW, Howland M. Antidotes in depth (A22): digoxin-specific antibody fragments. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. New York, NY: McGraw-Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7656506">
<a name="7656506"></a>Ujhelyi MR and Robert S, “Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity,” <i>Clin Pharmacokinet</i>, 1995, 28(6):483-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/7656506/pubmed" id="7656506" target="_blank">7656506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7664510">
<a name="7664510"></a>Varriale P and Mossavi A, “Rapid Reversal of Digitalis Delirium Using Digoxin Immune Fab Therapy,” <i>Clin Cardiol</i>, 1995, 18(6):351-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/7664510/pubmed" id="7664510" target="_blank">7664510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29941374">
<a name="29941374"></a>Wermuth ME, Vohra R, Bowman N, Furbee RB, Rusyniak DE. Cardiac toxicity from intentional ingestion of pong-pong seeds (<i>Cerbera Odollam</i>). <i>J Emerg Med.</i> 2018;55(4):507-511. doi:10.1016/j.jemermed.2018.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/29941374/pubmed" id="29941374" target="_blank">29941374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29382214">
<a name="29382214"></a>Wong A, Greene SL. Successful treatment of Nerium oleander toxicity with titrated digoxin Fab antibody dosing. <i>Clin Toxicol (Phila).</i> 2018;56(7):678-680. doi: 10.1080/15563650.2018.1432865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-immune-fab-drug-information/abstract-text/29382214/pubmed" id="29382214" target="_blank">29382214</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9361 Version 154.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
